Does giving pasireotide to patients undergoing pancreaticoduodenectomy always pay for itself?

ConclusionAt its current price, and with the fistula rate at our institution, pasireotide is more likely to pay for itself than not, but there is a  significant probability that it will not be cost-saving. Negotiating a better price (i.e., to the lowest found in the literature) will reduce the likelihood of pasireotide not being cost-saving by 5%.

Source: European Surgery - December 10, 2018 Category: Surgery Source Type: research